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Objective: To evaluate in inpatient and outpatient conditions, using
only non-calibration data, the accuracy of the Continuous Glucose
Monitoring System (CG-MS).
Research design and methods: Twelve, 21 and 20 type 1 diabetic
patients participated in 3- day inhospital, 6-day ambulatory (i.e., 2
sensors worn consecutively) and 3-day ambulatory studies. Capillary
glucose tests (7-8/day) served as comparisons. Pairs of data (exclud-
ing the 4 daily pairs used automatically by the CGMS for calibrations)
were analyzed using correlation coefficient, error -grid analysis, and
mean of absolute differences.
Results: Two third and half of the sensing days were qualified as
“optimal”, i.e., interpretable by the CGMS program in the inpatient and
outpatient studies, respectively. Correlation coefficient was 0.92, 0.81
and 0.73 in the inpatient, 6 day outpatient and 3-day outpatient stud-
ies. 98%, 93% and 96% of the data fell in the A or B error-grid
“clinically acceptable” zones. Mean absolute differences between sen-
sor and glucometer values were 25 ± 2, 34 ± 5 and 32 ± 5 mg/dl.
Conclusion: CGMS may be used for assessment of glycemic trends,
though accuracy is more in the range of glucometers than of labora-
tory tests. Inhospital utilisation improved accuracy and 6-day rather
than 3-day sessions may be more appropriate to evaluate day to day
reproducibility of glucose profile.
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Précision du capteur de glucose CGMS
chez le patient hospitalisé et le patient
ambulatoire
Objectifs : Evaluer dans des conditions d’hospitalisation et ambula-
toire, l’exactitude du capteur de glucose CGMS, en incluant seulement
les données hors calibration.
Matériels et méthodes : Douze, 21 et 20 diabétiques ont participé
respectivement à une étude intrahospitalière de 3 jours, une étude
ambulatoire de 6 jours (avec 2 capteurs posés consécutivement) et
une étude ambulatoire de 3 jours. Les glycémies capillaires (7 à 8 par
jour) ont servi de données de comparaison. Les données appariées,
excluant les 4 paires de données journalières utilisées pour la calibra-
tion automatique du CGMS, ont été analysées par les méthodes de
corrélation, d’erreur grid, et par le calcul de la moyenne des différen-
ces absolues.
Résultat : Deux tiers et la moitié des jours d’enregistrement ont été
qualifiés d’optimaux c’est-à-dire interprétables par le programme
CGMS chez les patients hospitalisés et au cours des études ambulatoi-
res respectivement. Les coefficients de corrélation étaient de 0,92, 0,
81 et 0,73 dans les études intrahospitalières, ambulatoires sur 6 jours,
et ambulatoires sur 3 jours. 98, 93 et 96 % des données se sont
situées dans les zones A et B de l’erreur grid c’est-à-dire les zones
“cliniquement acceptables”. La moyenne des différences absolues
entre le capteur et les lecteurs de glycémie a été de 25 ± 2, 34 ± 5 et 32
± 5 mg/dl.
Conclusion : Le CGMS peut être utilisé pour apprécier les “tendances-
”glycémiques même si son exactitude est plus proche de celle des
lecteurs glycémiques que de celle d’un appareil de laboratoire. L’utili-
sation intrahospitalière s’est avérée plus sûre et un enregistrement sur
6 jours plutôt que 3 jours dans les conditions ambulatoires, paraît plus
approprié pour évaluer la reproductibilité journalière du profil glycémi-
que.
Mots-clés : Capteur de glucose z Hypoglycémie z Pancréas artificiel.
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C ontinuous glucose sensing has made significantprogress in the last years, leading to commercialavailability of some externally worn subcutane-
ous devices including the “Glucowatch Biographer” [1] and
the Continuous Glucose Monitoring System (CGMS,
Medtronic Minimed, Northridge, Calif, USA) [2].
Though the latter system is now widely used, there is still
some questioning regarding the reliability of glucose moni-
toring [3]. Indeed, except in one article [4], a) it was not clear
whether calibrations points were excluded from evaluation
points to calculate accuracy, and b) the involvement of health
care team, as well as the percentage of interpretable days of
the continuous glucose monitoring sessions were not clearly
identified in the majority of publications. Finally, most of
those publications have involved directly or indirectly the
manufacturer itself [5-7].
Therefore, we decided a) to evaluate the accuracy of the
CGMS in inpatient conditions (i.e., CGMS was cared and
the control blood glucose was supervised by nurses) and out-
patient conditions (everything cared by patient), and b) to
analyze data excluding calibrations points and using the




The CGMS has been described in details elsewhere [2,
10]. Briefly it is a holter-style sensor system comprised of a) a
pager-size glucose monitor b) a disposable subcutaneous
needle-type enzymatic glucose electrode connected to the
monitoring by a cable. The data may be retrospectively
downloaded to a computer via a communication device and
a special program (version 1.7, used for all the recordings).
This program identifies the “interpretable days”, i.e., those
days when the automated comparisons between daily cali-
bration values and sensor values provide a correlation coeffi-
cient >0.79 and mean absolute difference <28% for a mini-
mum number of pairs of values of 3 within 24 h.
In patient study
Twelve type 1 diabetic patients (Tab I) gave written in-
formed consent and the study was approved by the hospital
ethical committee. The sensor was inserted by an experi-
enced nurse in the subcutaneous tissue of the abdominal wall
for a continuous monitoring of 3 days. Using a previously
validated glucometer (Glucotrend t Roche), i.e., a capillary
glucose value within 20% of a laboratory venous glycemia,
and a technique validated and supervised by a nurse, the
patients performed 8 capillary glucose tests over each 24 h
(one every 3 hours). Four values were used for automatic
calibration of the sensor, and 4 for evaluation of accuracy vs
capillary glucose values.
Out patient study
41 type 1 diabetic patients (Tab I) gave written informed
consent and the study was approved by the hospital ethical
committee. Twenty one patients used the sensor for up to 3
days, i.e., the nominal life of the sensor, and 20 for 6 days, i.e.,
they changed the sensor after 3 days. First insertion and edu-
cation for second insertion was realized during a clinic visit
in the hospital. The patients performed 7 capillary glucose
tests per 24 h using a Glucotrend t glucometer, including 4
values for automatic calibration and 3 for evaluation of accu-
racy of the sensor.
Statistical analyses
Only “optimal” days, i.e., the days identified by the
CGMS program as “interpretable” (see above) were used for
calculations. Accuracy vs capillary glucose was measured us-
ing 3 different methods: a) Spearman correlation coefficient,
b) Clarke error -grid analysis [8] and c) absolute differences




81 CGMS values (i.e., CGMS values at the time of capil-
lary glucose tests, excluding calibration values) were judged
by the CGMS program as interpretable over a number of 24
optimal days, i.e., one third of CGMS days were considered
as “non optimal” by the program. The average number of
calibration points was 4.2/day. Correlation coefficient was
0.92. Using the error-grid analysis, 82% and 16% of values
fell in the A and B zones, respectively, i.e., 98% of CGMS
values were in the “clinically acceptable” accuracy range
(Fig 1). Mean differences between CGMS and capillary glu-
cose values were 25 ± 2 (SEM) mg/dl (Fig 2A).
Outpatient study
The number of “optimal days” was 3.1 ± 1.9 (SD) and
1.5 ± 1.0 in the 6- day and 3- day sensing subgroups, respec-
Table I




6 day 3 day
n 12 21 20
Sex (M/F) 6/6 12/9 10/10
Age (yrs) 42 ± 15 46 ± 11 45 ± 12
Duration of
diabetes (yrs)
19 ± 11 21 ± 9 21 ± 12
Hba1c (%) 8.4 ± 1.1 7.7 ± 0.8 7.7 ± 0.8
C Djakouré-Platonoff et al.
Diabetes Metab 2003,29,159-62 • www.e2med.com/dm160
tively. Seventy nine pairs of data (excluding calibration val-
ues) were interpretable in the 6-day subgroup and 46 in the
3-day subgroup. The average number of calibration points
was 5.0 and 3.3/day, respectively.
Correlation coefficient was 0.81 and 0.73, respectively.
Error-grid analysis showed that 93% and 96% of CGMS
(Fig 1B and C) data fell in the A or B zones in the 6-day and
3-day subgroups, respectively. Mean absolute differences be-
tween CGMS and capillary glucose values were 34 ± 5 mg/dl











































































































Error - grid analysis of inpatient group (A), outpatient 6-day subgroup (B)
and 3-day subgroup (C) comparing CGMS glucose values to capillary




















































































Mean of absolute differences between CGMS data (y) and capillary glucose
values (x). Other legends as in figure 1.
Glycemic holter accuracy
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Discussion
Our results confirm data from literature showing accept-
able accuracy of the CGMS in patient and outpatient condi-
tions [4-7]. However correlation with blood glucose values
measured by a glucometer were slightly inferior to those
reported in the literature: 0.9 when sensor was used and
controlled in hospital under nurses supervisions, 0.8 when
used during 6 consecutive days at home, and 0.7 when used
during 3 days only at home. Differences between our data
and literature may be due to our evaluation strategy exclud-
ing pairs of data having served to calibration (usually 3 to 4
per day). Confirming this assumption, correlation coeffi-
cient rose to 0.91 and 0.88 in the 6-day and 3-day outpatient
studies when including calibration points into the calcula-
tion (data not shown), and are close to most recent reports
[11].
As claimed by manufacturer, CGMS data should not be
viewed as absolute values but as “trends” of glucose varia-
tions, i.e., shapes of the CGMS glucose profiles are more
important to consider than isolated values. Our data confirm
this view as we found global accuracy closer to the range of
glucometers than to those of laboratory measurements. We
cannot exclude that those differences may be due to the dif-
ferent milieus (blood vs interstitial fluid) where glucose was
measured [12].
Indeed, though error-grid analyses showed that more
than 90% of CGMS values were in the so called “clinically
acceptable range”, mean of absolute differences vs capillary
glucose levels were aproximately 25 mg/dl.
Finally, we found that interpretable days during the sens-
ing sessions varied between 1.5 to 2 out of the nominal 3 days
of a sensor lifetime, suggesting that 2 sensors should be used
consecutively (i.e., a total of 6 days, including 3 to 4 interpret-
able days), if one wants to appreciate the day-to-day repro-
ducibility of glucose profiles. We can only speculate that the
higher number of non interpretable days in our outpatients
groups may be due to more frequent technical problems e.g
disconnections.
In conclusion, our study confirms that CGMS may be
used reliably for global retrospective assessment of glycemic
fluctuations of patients though accuracy of evaluations of
nocturnal hypoglycemias is controversed [13].
Inhospital use may be required if better accuracy of data
is needed, and longer sessions may be required to better ana-
lyze glycemic reproducibility. Cost-effectiveness of the sys-
tem, though only potentially positive [14] should take into
account the 50-66% only, global good functioning of the sys-
tem.
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